| Meyer et al. (2022)16 UK Funding source: NR | Study design: SR with MA Last search date: December 2020 Number of included studies: 4 RCTs | Eligibility criteria: Studies that included patients who received pre-operative iron supplementation undergoing abdominal surgery Total number of patients included: 312 Sample size (range): 45 to 135 | Interventions (dose):Comparators: Placebo or usual care (undefined) | Outcomes:Risk of blood transfusion Death from randomization to post-operative day 30 Hemoglobin concentration at administration
Follow-up: NR |
| Tang et al. (2022)17 China Funding source: No funding | Study design: SR with MA Last search date: February 2021 Number of included studies: 7 (2 RCTs and 5 non-randomized studies) | Eligibility criteria: Studies that included patients who received iron supplementation undergoing surgery for colorectal cancer Total number of patients included: 879 Sample size (range): 45 to 318 | Interventions (dose):Pre-operative IV iron sucrose (600 mg) Post-operative IV iron saccharose (100 to 200 mg) Pre-operative IV iron carboxymaltose or iron isomaltoside (1,000 to 2,000 mg) Pre-operative IV iron sucrose (2 doses of 500 mg) or iron isomaltoside (1,000 mg or 20 mg/kg if bodyweight under 50 kg)
Comparators: No treatment; IV placebo; usual care (undefined) | Outcomes:Change in hemoglobin concentration Number of patients needed blood transfusion Iron-related adverse events
Follow-up: NR |
| Chaudhry et al. (2021)18 US Funding source: NR | Study design: SR Last search date: December 2019 Number of included studies: 7 RCTs | Eligibility criteria: Studies that included patients aged 18 years or older who received intra-operative or post-operative iron supplementation for elective TJA surgery Total number of patients included: 646 Sample size (range): 58 to 122 | Interventions (dose):Post-operative IV ferric carboxymaltose (700 to 1,000 mg) Intra-operative IV ferric carboxymaltose (1,000 mg) Intra-operative IV iron isomaltoside (≤ 20 mg/kg)
Comparators: Oral iron supplementation; placebo; no treatment | Outcomes:Change in hemoglobin levels Rate of post-operative anemia Rate of adverse events Post-operative QoL and functional outcomes
Follow-up: Varied by individual study or was NR |
| Elhenawy et al. (2021)19 Canada Funding source: NR | Study design: SR with MA Last search date: February 2019 Number of included studies: 10 RCTs | Eligibility criteria: Studies that included adult patients who received pre-operative IV iron supplementation for elective surgery Total number of patients included: 1039 Sample size (range): 56 to 203 | Interventions (dose):IV ferric carboxymaltose (1,000 mg) IV iron sucrose (2 doses of 300 mg) IV ferric carboxymaltose (15 mg/kg or up to 1,000 mg) IV iron sucrose (3 doses of 100 mg pre- and post-operative) IV iron (20 mg/kg or up to 1,000 mg) IV iron sucrose (3 doses of 200 mg) IV iron sucrose (100 mg per dose for 4 weeks as needed) IV iron sucrose (200 mg)
Comparators: Placebo; usual care (undefined); oral iron supplementation | Outcomes:Follow-up: Varied by study but ranged from hospital discharge to 3 months post-hospital discharge |
| Jones et al. (2021)20 US Funding source: Peloton Advantage, LLC funded by American Regent, Inc. | Study design: SR Last search date: January 2021 Number of included studies: 10 RCTs | Eligibility criteria: Studies that included adult patients who underwent elective surgery and received IV iron supplementation Total number of patients included: 1975 Sample size (range): 44 to 481 | Interventions (dose):Post-operative IV ferric carboxymaltose (700 to 1,000 mg) Pre-operative IV ferric carboxymaltose (15 mg) and post-operative IV ferric carboxymaltose (0.5 mg per 1 ml blood loss) Post-operative IV ferric carboxymaltose (15 mg/kg or maximum 1,000 mg) Pre-operative IV ferric carboxymaltose (1,000 mg/week or 2,000 mg during trial) Pre-operative IV ferric carboxymaltose (1 to 2 doses of 1,000 mg for patients <50 kg or 500 mg for patients ≥50 kg) Pre-operative IV ferric carboxymaltose (maximum 1,000 mg)
Comparators: Placebo; usual care, oral iron supplementation; no treatment | Outcomes:Follow-up: Varied by individual study or was NR |
| Moon et al. (2021)21 US Funding source: No funding | Study design: SR Last search date: November 2020 Number of included studies: 9 (5 RCTs and 4 non-randomized studies) | Eligibility criteria: Studies that included adult patients who underwent elective abdominal surgery and received pre-operative IV iron supplementation Total number of patients included: 1817 Sample size (range): 60 to 487 | Interventions (dose):IV ferric carboxymaltose (1 dose of 1,000 mg) IV iron sucrose (2 doses of 300 mg) IV ferric carboxymaltose (3 doses of 1,000 mg) Pre-operative IV ferric carboxymaltose (1,000 mg) and post-operative IV ferric carboxymaltose (0.5 mg/L blood loss) IV iron sucrose (dose unspecified) IV iron sucrose or ferric carboxymaltose (dose unspecified) IV ferric carboxymaltose (1,000 to 2,000 mg) IV iron sucrose (500 mg) or IV iron isomaltoside (1,000 mg)
Comparators: Placebo; oral iron supplementation; no treatment | Outcomes:Risk of blood transfusion Number of transfusion episodes Change in hemoglobin levels Mortality
Follow-up: Varied by individual study or was NR |
